Sciencast Management LP Grows Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sciencast Management LP raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 35.5% during the fourth quarter, HoldingsChannel reports. The fund owned 9,131 shares of the medical equipment provider’s stock after buying an additional 2,391 shares during the period. Sciencast Management LP’s holdings in Zimmer Biomet were worth $965,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of ZBH. Empowered Funds LLC grew its stake in shares of Zimmer Biomet by 6.8% in the third quarter. Empowered Funds LLC now owns 4,135 shares of the medical equipment provider’s stock worth $446,000 after acquiring an additional 265 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Zimmer Biomet by 21.3% in the third quarter. Intech Investment Management LLC now owns 2,379 shares of the medical equipment provider’s stock worth $257,000 after acquiring an additional 417 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Zimmer Biomet during the third quarter valued at $884,000. Foundry Partners LLC boosted its position in shares of Zimmer Biomet by 6.1% during the third quarter. Foundry Partners LLC now owns 5,559 shares of the medical equipment provider’s stock valued at $600,000 after buying an additional 322 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Zimmer Biomet by 0.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,006,217 shares of the medical equipment provider’s stock valued at $108,621,000 after buying an additional 4,388 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on ZBH shares. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus increased their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Royal Bank of Canada dropped their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Stock Down 0.9 %

Shares of ZBH opened at $110.79 on Friday. The stock has a market capitalization of $22.05 billion, a price-to-earnings ratio of 24.90, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90. The business’s 50 day simple moving average is $106.74 and its 200-day simple moving average is $106.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company posted $2.20 EPS. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Insider Activity

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.95% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.